GRAd-COV2 Uses, Dosage, Side Effects and more
GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera. This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2). Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses.
| Trade Name | GRAd-COV2 |
| Generic | GRAd-COV2 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
